cell
provid
broad
immun
virus
abl
recogn
type
viral
protein
therefor
develop
vaccin
capabl
induc
longliv
memori
cell
desir
prevent
diseas
especi
vaccin
current
exist
howev
design
cell
vaccin
role
cell
induct
mainten
memori
cell
remain
uncertain
present
studi
necess
cell
induct
mainten
memori
cell
investig
mice
immun
liposomecoupl
ctl
epitop
peptid
ovaderiv
ctl
epitop
peptid
chemic
coupl
surfac
liposom
inocul
mice
primari
secondari
ctl
respons
success
induc
result
confirm
cellelimin
mice
suggest
cell
requir
gener
memori
cell
case
immun
liposomecoupl
peptid
thu
surfacelink
liposom
antigen
capabl
induc
longliv
memori
cell
without
contribut
cell
might
applic
develop
vaccin
prevent
viral
infect
especi
virus
evad
humor
immun
vari
surfac
protein
influenza
virus
hiv
hcv
sar
coronavirus
ebola
virus
report
numer
investig
cell
essenti
mainten
memori
cell
howev
induct
mainten
memori
cell
differ
role
cell
describ
socal
classic
model
cell
contribut
memori
tcell
gener
indirectli
via
apc
interact
cell
apc
cell
licens
apc
induct
memori
cell
altern
apc
licens
model
bourgeoi
et
al
provid
evid
demonstr
cell
contribut
directli
cell
cell
rather
indirectli
via
apc
howev
find
counter
studi
longliv
memori
cell
gener
absenc
express
cell
addit
role
interact
induct
memori
cell
hernandez
et
al
report
cell
provid
order
licens
apc
induct
memori
cell
scenario
although
interact
cell
dc
indispens
induct
memori
cell
cell
necessarili
involv
thu
research
far
resolv
role
cell
induct
mainten
memori
cell
although
resolv
issu
critic
step
design
better
vaccin
immunotherapeut
strategi
upon
natur
infect
host
respond
induc
humor
cellular
immun
pathogen
humor
immun
respons
repres
product
antibodi
bind
surfac
bacteria
virus
wherea
cellular
immun
respons
mediat
immun
intracellular
pathogen
gener
extracellular
antigen
present
via
mhc
class
ii
molecul
cell
wherea
intracellular
antigen
present
via
mhc
class
molecul
cell
induc
antigenspecif
ctl
antigen
must
load
onto
class
mhc
process
pathway
apc
via
crosspresent
crosspresent
exogen
protein
cross
endogen
pathway
gain
access
mhc
class
molecul
use
phenomenon
gener
antigenspecif
ctl
respons
might
use
develop
vaccin
prevent
viral
diseas
howev
current
approv
alum
adjuv
first
describ
glenni
et
al
today
remain
adjuv
approv
clinic
use
known
effect
induct
humor
immun
induct
cellmedi
immun
consequ
develop
novel
vaccin
adjuv
essenti
induct
cellmedi
immun
previous
report
surfacecoupl
liposom
antigen
could
present
apc
cell
via
mhc
class
molecul
certain
lipid
compon
chosen
liposom
antigen
prepar
expect
applic
develop
tumor
vaccin
induc
antitumor
respons
develop
viral
vaccin
induc
virusspecif
ctl
effect
elimin
virusinfect
cell
sinc
liposom
conjug
induc
ctl
effici
ctl
epitop
peptid
coupl
surfac
liposom
liposom
conjugatesar
expect
applic
develop
ctlbase
peptid
vaccin
develop
peptid
vaccin
essenti
know
whether
helper
epitop
peptid
necessari
induct
longliv
memori
cell
import
step
vaccin
prepar
studi
aim
evalu
role
cell
induct
longliv
memori
cell
liposomecoupl
peptid
induct
antigenspecif
primari
cell
ctl
mice
ova
liposom
conjug
mice
immun
ova
liposom
conjug
presenc
cpg
describ
materi
method
signific
induct
ctl
specif
ova
observ
day
complet
cell
kill
observ
earli
day
immun
figur
therefor
follow
experi
primari
ctl
respons
monitor
day
immun
mice
immun
serial
dilut
solut
ova
liposom
conjug
contain
mg
peptid
ova
solut
contain
equal
amount
peptid
liposom
conjug
although
ova
liposom
ova
solut
seem
induc
compar
level
tcell
cytokin
product
highest
dose
mginject
dosedepend
decreas
observ
mice
immun
ova
solut
mice
immun
ova
liposom
suggest
ova
liposom
effect
ova
solut
induct
antigenspecif
cell
cytokin
product
figur
similar
result
observ
cell
cytokin
product
dose
ova
liposom
low
mgmous
dilut
induc
perfect
kill
assay
vivo
ctl
assay
ova
solut
induc
partial
kill
even
highest
dose
figur
week
later
mice
receiv
booster
inject
ova
three
day
booster
inject
ova
specif
cell
kill
monitor
shown
figur
complet
cell
kill
observ
week
immun
without
booster
inject
week
immun
signific
recal
respons
observ
upon
booster
inject
ova
inocul
naiv
mice
dose
ova
booster
inject
imm
figur
induc
detect
ctl
respons
interestingli
signific
recal
respons
observ
even
week
primari
ctl
respons
nearli
undetect
antigenspecif
tcell
prolifer
assay
confirm
result
shown
figur
cell
mice
immun
ova
significantli
prolifer
upon
vitro
stimul
ova
even
week
immun
elimin
cell
mice
inocul
describ
materi
method
immun
ova
liposom
shown
figur
vivo
elimin
cell
affect
neither
primari
figur
secondari
figur
ctl
respons
even
week
immun
signific
recal
respons
compar
normal
mice
observ
mice
cell
elimin
present
studi
role
cell
induct
mainten
memori
cell
evalu
mice
immun
liposomecoupl
ctl
epitop
peptid
although
inclus
cpg
ligand
need
induct
primari
ctl
respons
ova
cell
requir
either
primari
secondari
respons
sinc
longliv
memori
cell
readili
induc
immun
ctl
epitop
peptid
coupl
liposom
figur
find
confirm
celldeplet
mice
figur
result
agreement
report
previous
numer
investig
cell
dispens
primari
expans
cell
differenti
cytotox
effector
howev
research
claim
secondari
ctl
expans
wholli
depend
presenc
helper
cell
prime
previous
report
surfacelink
liposom
antigen
induc
igeselect
unrespons
result
consist
even
differ
coupl
procedur
antigen
liposom
employ
cours
investig
intend
clarifi
mechan
igeselect
unrespons
induc
surfacecoupl
liposom
antigen
discov
altern
approach
regul
product
ige
one
independ
activ
cell
immun
mice
ovaliposom
conjug
induc
igeselect
unrespons
without
appar
polar
neither
cell
particip
regul
cell
mice
immun
ovaliposom
capabl
induc
antigenspecif
ige
synthesi
athym
nude
mice
immun
alumadsorb
ova
hand
immun
recipi
mice
ovaliposom
induc
antiova
ige
product
even
cell
mice
immun
alumadsorb
ova
transfer
secondari
immun
respons
ovaliposom
enhanc
antiova
igg
antibodi
product
enhanc
ongo
ige
product
suggest
igeselect
unrespons
induc
liposom
antigen
involv
direct
effect
ige
igg
switch
vivo
result
suggest
role
altern
mechan
one
involv
cell
regul
ige
synthesi
rais
possibl
surfacelink
liposom
antigen
potenti
applic
develop
novel
vaccin
minim
induct
ige
synthesi
moreov
given
rel
low
allerg
respons
increas
antigen
allergen
form
antigen
prepar
would
applic
allergen
immunotherapi
potenti
use
surfacelink
liposom
antigen
applic
vaccin
develop
investig
cours
investig
signific
differ
observ
recognit
liposom
antigen
antigenpres
cell
apc
liposom
differ
lipid
compon
differ
close
correl
adjuv
activ
liposom
addit
quantit
differ
liposom
differ
lipid
compon
qualit
differ
ie
differ
abil
induc
crosspresent
also
observ
liposom
differ
lipid
compon
although
precis
mechan
underli
differ
current
unclear
signific
differ
membran
mobil
observ
liposom
might
affect
abil
induc
crosspresent
thu
util
abil
induc
crosspresent
surfacelink
liposom
antigen
could
use
develop
viru
vaccin
induc
cytotox
tcell
ctl
respons
well
tumor
vaccin
prepar
present
tumor
antigen
apc
induc
effect
antitumor
respons
regard
necess
cell
gener
memori
cell
result
present
studi
differ
report
previous
differ
find
may
due
differ
mice
prime
antigen
studi
report
previous
mice
prime
infect
virus
lcmv
influenza
viru
recombin
vaccinia
viru
wherea
present
studi
mice
immun
ovaderiv
ctl
epitop
peptid
perhap
differ
requir
cell
observ
among
studi
present
studi
due
differ
effici
induc
present
immunodomin
ctl
epitop
apc
gener
peptid
foreign
antigen
express
appropri
apc
achiev
immunodomin
statu
given
class
allel
howev
present
studi
immun
ova
liposom
success
induc
primari
secondari
ctl
respons
without
presenc
cell
figur
addit
report
previous
antigen
coupl
surfac
liposom
recogn
effect
apc
present
cell
therefor
although
tlrligand
cpg
present
studi
necessari
mimic
viral
infect
order
induc
ctl
respons
immun
liposomecoupl
peptid
cell
requir
induct
mainten
memori
cell
consider
interest
develop
vaccin
elicit
effect
antivir
cell
respons
varieti
virus
hiv
hcv
sar
coronaviru
purpos
util
immunodomin
ctl
epitop
would
effect
use
attenu
inactiv
subunit
vaccin
develop
viru
vaccin
elicit
effect
antivir
cell
respons
exampl
although
risk
major
global
pandem
avian
influenza
creat
widespread
concern
vaccin
design
induc
antibodi
haemagglutinin
expect
possess
littl
efficaci
given
high
rate
diversif
strain
due
antigen
drift
caus
point
mutat
gene
hand
known
cytotox
cell
specif
intern
protein
np
show
high
crossreact
strain
subtyp
reflect
high
conserv
intern
protein
addit
lee
et
al
recent
report
peopl
expos
virus
crossreact
cell
memori
wide
rang
peptid
therefor
peptid
expect
use
add
cell
compon
current
antibodyfocus
vaccin
strategi
view
reduc
impact
infect
novel
influenza
virus
epstein
et
al
studi
dna
vaccin
mice
plasmid
express
conserv
nucleoprotein
np
matrix
viru
howev
dna
vaccin
alon
protect
poorli
highli
virul
strain
influenza
virus
recent
report
peptid
deriv
intern
np
protein
influenza
viru
chemic
coupl
surfac
liposom
induc
antigenspecif
ctl
success
inhibit
growth
influenza
viru
lung
recent
determin
human
hla
class
irestrict
immunodomin
ctl
epitop
deriv
intern
protein
influenza
virus
similar
result
report
previous
ctl
epitop
determin
well
conserv
ident
involv
influenza
virus
combin
use
ctl
epitop
peptid
common
influenza
virus
surfacelink
liposom
antigen
induc
longliv
memori
cell
without
cell
help
demonstr
applic
develop
ctlbase
influenza
vaccin
capabl
induc
protect
heterosubtyp
influenza
virus
taken
togeth
result
suggest
surfacelink
liposom
antigen
might
applic
develop
ctlbase
vaccin
induc
longterm
prevent
infect
virus
influenza
virus
especi
virus
evad
humor
immun
vari
surfac
protein
hiv
hcv
sar
coronavirus
mice
mice
wk
age
purchas
slc
shizuoka
japan
mice
maintain
specif
pathogenfre
condit
experi
present
studi
approv
permit
number
anim
research
committe
nation
institut
infecti
diseas
tokyo
japan
mice
handl
accord
intern
guidelin
experi
anim
phospholipid
obtain
nof
co
tokyo
japan
reagent
grade
cholesterol
purchas
wako
pure
chemic
osaka
japan
ovalbumin
ova
grade
vii
purchas
sigmaaldrich
mous
mhc
classi
k
b
bind
peptid
ova
siinfekl
obtain
operon
biotechnolog
tokyo
japan
synthet
cpg
odn
tccatgacgttcttgatgtt
phosphorothioateprotect
avoid
nucleasedepend
degrad
purchas
invitrogen
liposom
use
studi
provid
nof
corpor
tokyo
japan
consist
dioleoyl
phosphatidylcholin
dopc
dioleoyl
phosphatidyl
ethanolamin
dope
dioleoyl
phosphatidyl
glycerol
dopg
cholesterol
molar
ratio
crude
liposom
solut
pass
membran
filter
nucleopor
polycarbon
filter
coster
pore
size
mm
liposom
conjug
ova
peptid
prepar
essenti
way
describ
previous
via
disuccinimidyl
suber
dss
briefli
mixtur
ml
anhydr
chloroform
solut
contain
mm
dope
ml
tea
ad
drop
ml
anhydr
chloroform
solut
contain
mm
dss
stir
h
solvent
evapor
reduc
pressur
ml
mixtur
ethyl
acet
tetrahydrofuran
ad
dissolv
residu
ml
sodium
phosphat
ph
ml
satur
nacl
aqueou
solut
ad
solut
shaken
min
allow
separ
remov
undesir
materi
upper
layer
wash
buffer
evapor
solvent
ml
aceton
ad
dissolv
residu
one
hundr
ml
icecold
aceton
ad
drop
kept
ice
min
precipit
crystal
collect
dissolv
ml
chloroform
evapor
mg
dopedss
obtain
mm
dopc
mm
dopedss
mm
cholesterol
mm
dopg
dissolv
ml
chloroformmethanol
solvent
remov
reduc
pressur
ml
phosphat
buffer
ph
ad
make
lipid
suspens
vesicl
dispers
extrud
polycarbon
filter
adjust
liposom
size
suspens
dssintroduc
liposom
ml
ova
peptid
solut
mix
stir
day
liposomecoupledand
uncoupl
peptid
separ
describ
use
column
chromatographi
result
solut
ova
liposom
conjug
contain
mgml
peptid
assess
aminoacid
quantit
analysi
done
toray
research
center
kanagawa
japan
mice
immun
indic
dose
ova
liposom
conjug
via
subctan
inject
presenc
mgmous
cpg
booster
immun
mice
immun
intraperiton
ip
ml
ml
ova
pb
solut
vivo
elimin
cell
vivo
elimin
cell
mice
receiv
weekli
ip
inject
mg
monoclon
antibodi
throughout
experiment
period
treatment
result
decreas
number
cell
spleen
lymph
node
determin
fluorescenceactiv
cell
sorter
fac
analysi
spleen
cell
naiv
mice
label
either
mm
dull
mm
bright
cfse
min
use
cell
trace
cfse
cell
prolifer
kit
molecular
probe
eugen
wash
twice
icecold
pb
cfsebright
cell
subsequ
puls
mgml
ova
min
cfsebright
cell
cfsedul
cell
mix
ratio
total
cell
inject
iv
indic
group
mice
twenti
hour
later
spleen
cell
harvest
mous
analyz
use
facscalibur
becton
dickinson
mountain
view
ca
incub
perform
invitrogen
life
technolog
supplement
heatinactiv
fc
hyclon
uml
penicillin
mgml
streptomycin
invitrogen
dc
cell
obtain
spleen
cell
mice
use
magnet
cell
sorter
system
mac
accord
manufactur
protocol
use
antibodyco
microbead
miltenyi
biotec
respect
cell
dc
suspend
contain
fc
cell
densiti
ml
ml
respect
cell
suspens
plate
ml
per
well
onto
cultur
plate
bd
bioscienc
ml
dc
suspens
ml
mm
ova
solut
medium
ad
plate
incub
co
incub
day
cultur
supernat
collect
assay
concentr
ifnc
ifnc
cultur
supernat
measur
use
biotrak
mous
elisa
system
ge
healthcar
uk
test
sampl
assay
duplic
se
test
alway
less
mean
valu
splenic
cell
cellswel
immun
mice
whole
spleen
cell
cellswel
gyirradi
mice
cultur
plate
day
presenc
close
box
absenc
open
box
mm
ova
cell
puls
mci
mbq
h
thymidin
perkinelm
final
hour
cultur
harvest
cell
prolifer
monitor
use
topcount
perkinelm
student
test
employ
statist
analysi
conceiv
design
experi
tu
perform
experi
mt
yt
tk
analyz
data
mt
tu
contribut
reagent
materialsanalysi
tool
mt
yt
wrote
paper
tu
na
